Published by Oliver Haill on 22nd June 2018
(Sharecast News) - Cancer-focused biopharma company Autolus Therapeutics priced its Nasdaq initial public offer at the top end of its $15-17 indicated range ahead of its trading debut on Friday, giving a boost for London-listed backers Syncona, Woodford Patient Capital fund and Arix Bioscience.